All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2020; the latest 2023-08-04.
From the record
Taysha Gene Therapies, Inc.'s filings since 2020 show 2 warning events: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2023-08-04) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+57.5% a year over 4 filed years; profitable in 0 of 4.
From the record
Taysha Gene Therapies, Inc.'s 4 filed years say what it did: revenue went from $3 million in fiscal 2022 to $10 million in fiscal 2025, up 57.5% a year; it rose in 2 of 3 years; the deepest fall was 46% from fiscal 2023 to fiscal 2024; net income was positive in 0 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 1.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Taysha Gene Therapies, Inc.'s shareholder treatment is put at 1.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 15% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -44%: lost 44¢ per shareholder dollar. Leverage 28%: owes 28¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Taysha Gene Therapies, Inc. lost about 44 cents for every dollar of shareholders' money. Leverage: it owed about 28 cents per dollar of assets, and net share issuance: its share count grew 27.8% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 50% of 102 in its family; net margin -1115.3%.
From the record
Taysha Gene Therapies, Inc.'s standing among 102 graded names in its industry family: revenue of $10 million in fiscal 2025 ranks in the bottom 37% by size; a net margin of -1115.3% ranks in the bottom 32%; revenue growth of 57.5% a year over the last 3 filed years ranks in the top 17% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 33% of 110 in its family for leadership; chief executive since 2023.
From the record
Taysha Gene Therapies, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Nolan, Sean P. (Chief Executive Officer, as filed), filing under that title since 2023-01-04, 3.9 years (bottom 40% of its family); the 7 officers and directors filing in the last fifteen months have been on the record a median of 6.1 years (top 31%); 1 officer or director change was reported on Form 8-K since 2023-11-13, against the 7 people in charge now (top 10%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 39% of 92 in its family for room to expand.
From the record
Taysha Gene Therapies, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $320 million against debt of $50 million leaves 78.5% of its assets as net cash, top 15% of its family; cash from operations less capital spending is -960.1% of revenue (bottom 28%); research spending of 884.1% of revenue (top 28%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 41% of 100 in its family for growth drivers.
From the record
Taysha Gene Therapies, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 57.5% a year over the last three filed years against 57.5% over all 4, speeding up (top 36% of its family); the newest year grew 17.3% (top 48%); research spending grew -1.8% a year (bottom 41%); capital spending grew -67% a year (bottom 9%) (its annual reports). Taysha Gene Therapies, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 49% of 72 in its family for expectations against reality.
From the record
Taysha Gene Therapies, Inc.'s newest year against its own record: revenue of $10 million in fiscal 2025 came in 35.7% below the $15 million its prior three years' pace pointed to (bottom 19% of its family); net income of $109 million against a prior three-year average of $122 million (bottom 49%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 15%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made